Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 9/20 | 0.43 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | DPEP1 | P16444 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054542 | 0.81 | HPGD (0.43) | RAB9A | |
| SCHEMBL5053008 | 0.79 | ANPEP (0.41) | NPC1RAB9A | |
| SCHEMBL5051251 | 0.78 | SRR (0.56) | ACE | |
| SCHEMBL4451525 | 0.77 | EPHX2 (0.46) | ATMMETAP2METAP1LTA4HNPC1 | |
| SCHEMBL5054450 | 0.76 | CETP (0.43) | ACE | |
| SCHEMBL5053043 | 0.75 | MMP1 (0.61) | MMP1MMP13ATM | |
| SCHEMBL5057950 | 0.75 | PPARG (0.50) | ACP3 | |
| SCHEMBL9265345 | 0.75 | SLC1A3 (0.45) | ATMMETAP2METAP1LTA4HNPC1 | |
| SCHEMBL5051224 | 0.74 | LTA4H (0.50) | MMP1MMP13LTA4HNPC1RAB9A | |
| SCHEMBL5060067 | 0.74 | PPARG (0.47) | MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6384022-B1 | ENZYME INHIBITORS | GUILFORD PHARMACEUTICALS INC. | 2002-05-07 | — | — | US | disclosed |
| US-6372726-B1 | ADMINISTERING CARBOXYALKYL PHOSPHONATE, PHOSPHORAMIDATE, OR PHOSPHINE OXIDE DERIVATIVE AS ANTITUMOR AGENT TO TREAT CANCER OF PROSTATE GLAND | GUILFORD PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | disclosed |
| US-6011021-A | GLUTAMATE-DERIVED HYDROXYPHOSPHINYL DERIVATIVE. | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | REN 903/4885MMP1 115/4885MMP13 102/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | REN 449/4885MMP1 1631/4885MMP13 903/4885 |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | REN 2630/4885MMP1 831/4885MMP13 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.